AbbVie (ABBV.US) raised its Q2 EPS guidance by 2%, supported by strong performance from Credit Suisse, who maintained a "buy" rating.
According to the Zhtng Cijng APP, a research update on AbbVie Inc. (ABBV.US) 2Q25 financial report recently released by Morgan Stanley showed that the company's 2Q25 revenue and EPS both exceeded expectations, with revenue reaching $15.423 billion (a year-on-year increase of 7%) and EPS at $2.97 (a year-on-year increase of 12%), and raised its 2025 EPS guidance by 2%. Skyrizi and Rinvoq performed better than consensus expectations, while Humira and Juvederm did not meet expectations. The bank expects its stock price to rise and maintains a "hold" rating.
Latest